

## Association des Medecins Oncologues Privés

**Objet:** Support of the application for the inclusion of Pertuzumab to the 23rd Edition of the WHO Essential Medicines List (EML) 2021

Dear Committee Member,

On behalf of the Association of Medical Oncologist in Private (AMOP), I submit this letter in support of the request to add Pertuzumab to the WHO Model list of Essentiel Medicine under

the category of cytotoxic and adjuvant medicines as a new medicines for the treatment of HER2

metastatic breast cancer.

In the treatment of adult patients with HER2-positive breast cancer, Pertuzumab offer substantial clinical benefit across all indications (neoadjuvant, adjuvant and metastatic) in combination with Trastuzumab and chemotherapy. Pertuzumab is considered as the standard of care which improve the outcome of patients and make a real difference in patients life worldwide.

However, in Tunisia as in low and middle income countries, the access to Pertuzumab remain a challenge with a low rate of patient who received the treatments.

As a scientifics Experts we believe that a recognition by the WHO of Pertuzumab as an essential medicine, similarly as Trastuzumab in 2015, would be timely and a significant step to broaden Pertuzumab's access to more patients not only in Tunisia but around the globe, hence tackling breast cancer more equitably, effectively, and ultimately driving better outcomes for patients.

We respectfully urge the committee to consider the additional lives that could be saved or improved with expanded access to Pertuzumab and accept the proposal for the inclusion of Pertuzumab to the 23rd Edition of the WHO Essential Medicines List (EML) 2021

Yours Faithfully

